Kathleen Metters

HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA.

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.

Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases.